Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

460 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Improving prediction of psychosis in youth at clinical high-risk: pre-baseline symptom duration and cortical thinning as moderators of the NAPLS2 risk calculator.
Worthington MA, Collins MA, Addington J, Bearden CE, Cadenhead KS, Cornblatt BA, Keshavan M, Mathalon DH, Perkins DO, Stone WS, Walker EF, Woods SW, Cannon TD. Worthington MA, et al. Among authors: addington j. Psychol Med. 2024 Feb;54(3):611-619. doi: 10.1017/S0033291723002301. Epub 2023 Aug 29. Psychol Med. 2024. PMID: 37642172
The PRIME North America randomized double-blind clinical trial of olanzapine versus placebo in patients at risk of being prodromally symptomatic for psychosis. I. Study rationale and design.
McGlashan TH, Zipursky RB, Perkins D, Addington J, Miller TJ, Woods SW, Hawkins KA, Hoffman R, Lindborg S, Tohen M, Breier A. McGlashan TH, et al. Among authors: addington j. Schizophr Res. 2003 May 1;61(1):7-18. doi: 10.1016/s0920-9964(02)00439-5. Schizophr Res. 2003. PMID: 12648731 Clinical Trial.
The PRIME North America randomized double-blind clinical trial of olanzapine versus placebo in patients at risk of being prodromally symptomatic for psychosis. II. Baseline characteristics of the "prodromal" sample.
Miller TJ, Zipursky RB, Perkins D, Addington J, Woods SW, Hawkins KA, Hoffman R, Preda A, Epstein I, Addington D, Lindborg S, Marquez E, Tohen M, Breier A, McGlashan TH. Miller TJ, et al. Among authors: addington d, addington j. Schizophr Res. 2003 May 1;61(1):19-30. doi: 10.1016/s0920-9964(02)00440-1. Schizophr Res. 2003. PMID: 12648732 Clinical Trial.
Social outcome in early psychosis.
Addington J, Young J, Addington D. Addington J, et al. Among authors: addington d. Psychol Med. 2003 Aug;33(6):1119-24. doi: 10.1017/s0033291703007815. Psychol Med. 2003. PMID: 12946096
Factorial structure of the Scale of Prodromal Symptoms.
Hawkins KA, McGlashan TH, Quinlan D, Miller TJ, Perkins DO, Zipursky RB, Addington J, Woods SW. Hawkins KA, et al. Among authors: addington j. Schizophr Res. 2004 Jun 1;68(2-3):339-47. doi: 10.1016/S0920-9964(03)00053-7. Schizophr Res. 2004. PMID: 15099615
Randomized, double-blind trial of olanzapine versus placebo in patients prodromally symptomatic for psychosis.
McGlashan TH, Zipursky RB, Perkins D, Addington J, Miller T, Woods SW, Hawkins KA, Hoffman RE, Preda A, Epstein I, Addington D, Lindborg S, Trzaskoma Q, Tohen M, Breier A. McGlashan TH, et al. Among authors: addington d, addington j. Am J Psychiatry. 2006 May;163(5):790-9. doi: 10.1176/ajp.2006.163.5.790. Am J Psychiatry. 2006. PMID: 16648318 Clinical Trial.
460 results